Outcomes of 167 healthy sibling donors after peripheral blood stem cell mobilization with G-CSF 16 mu g/kg/day: efficacy and safety
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00084608" target="_blank" >RIV/00216224:14110/15:00084608 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/65269705:_____/15:00063399
Výsledek na webu
<a href="http://dx.doi.org/10.4149/neo_2015_094" target="_blank" >http://dx.doi.org/10.4149/neo_2015_094</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.4149/neo_2015_094" target="_blank" >10.4149/neo_2015_094</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Outcomes of 167 healthy sibling donors after peripheral blood stem cell mobilization with G-CSF 16 mu g/kg/day: efficacy and safety
Popis výsledku v původním jazyce
Mobilization of peripheral blood stem cells (PBSC) using the granulocyte colony-stimulating factor (G-CSF) has enabled the collection even from older donors and those with comorbidities. Several clinical parameters have been reported to predict the success of PBSC mobilization. The aim of our study was to evaluate the safety of PBSC donation in a cohort of 167 sibling donors after mobilization with G-CSF 16 mu g/kg/day for 5 days during short- and long term follow-up and to analyse the efficacy, toxicity and factors influencing CD34+ mobilization capacity. All 167 sibling donors completed the established mobilization protocol. The median yield was 7.9x10(6)CD34 cells/kg per recipient weight. The optimal target dose of CD34 cells >= 4.0x10(6)/kg wasachieved in 140 donors (84%). Only in 4 donors (2%) was the CD34+ yield < 2x10(6)/kg. No major toxicities occured. Factors associated with higher PBSC yields included age < 55 years (p=0.001), male gender (p=0.
Název v anglickém jazyce
Outcomes of 167 healthy sibling donors after peripheral blood stem cell mobilization with G-CSF 16 mu g/kg/day: efficacy and safety
Popis výsledku anglicky
Mobilization of peripheral blood stem cells (PBSC) using the granulocyte colony-stimulating factor (G-CSF) has enabled the collection even from older donors and those with comorbidities. Several clinical parameters have been reported to predict the success of PBSC mobilization. The aim of our study was to evaluate the safety of PBSC donation in a cohort of 167 sibling donors after mobilization with G-CSF 16 mu g/kg/day for 5 days during short- and long term follow-up and to analyse the efficacy, toxicity and factors influencing CD34+ mobilization capacity. All 167 sibling donors completed the established mobilization protocol. The median yield was 7.9x10(6)CD34 cells/kg per recipient weight. The optimal target dose of CD34 cells >= 4.0x10(6)/kg wasachieved in 140 donors (84%). Only in 4 donors (2%) was the CD34+ yield < 2x10(6)/kg. No major toxicities occured. Factors associated with higher PBSC yields included age < 55 years (p=0.001), male gender (p=0.
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2015
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Neoplasma
ISSN
0028-2685
e-ISSN
—
Svazek periodika
62
Číslo periodika v rámci svazku
5
Stát vydavatele periodika
SK - Slovenská republika
Počet stran výsledku
6
Strana od-do
787-792
Kód UT WoS článku
000362389600013
EID výsledku v databázi Scopus
—